DexCom Statistics

Total Valuation

DexCom has a market cap or net worth of EUR 28.89 billion. The enterprise value is 28.79 billion.

Market Cap	28.89B
Enterprise Value	28.79B

Important Dates

The next estimated earnings date is Thursday, July 24, 2025.

Earnings Date	Jul 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	392.11M
Shares Outstanding	n/a
Shares Change (YoY)	-3.45%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	389.38M

Valuation Ratios

The trailing PE ratio is 58.35 and the forward PE ratio is 38.64.

PE Ratio	58.35
Forward PE	38.64
PS Ratio	7.53
PB Ratio	13.78
P/TBV Ratio	14.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.76, with an EV/FCF ratio of 54.10.

EV / Earnings	58.14
EV / Sales	8.13
EV / EBITDA	37.76
EV / EBIT	53.32
EV / FCF	54.10

Financial Position

The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.14.

Current Ratio	1.50
Quick Ratio	1.27
Debt / Equity	1.14
Debt / EBITDA	2.89
Debt / FCF	4.49
Interest Coverage	33.12

Financial Efficiency

Return on equity (ROE) is 23.72% and return on invested capital (ROIC) is 8.16%.

Return on Equity (ROE)	23.72%
Return on Assets (ROA)	5.98%
Return on Invested Capital (ROIC)	8.16%
Return on Capital Employed (ROCE)	17.03%
Revenue Per Employee	374,413
Profits Per Employee	48,309
Employee Count	10,300
Asset Turnover	0.63
Inventory Turnover	2.90

Taxes

In the past 12 months, DexCom has paid 180.97 million in taxes.

Income Tax	180.97M
Effective Tax Rate	26.77%

Stock Price Statistics

The stock price has decreased by -26.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-26.03%
50-Day Moving Average	71.50
200-Day Moving Average	71.34
Relative Strength Index (RSI)	50.55
Average Volume (20 Days)	245

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.27

Income Statement

In the last 12 months, DexCom had revenue of EUR 3.84 billion and earned 495.17 million in profits. Earnings per share was 1.23.

Revenue	3.84B
Gross Profit	2.28B
Operating Income	585.28M
Pretax Income	676.14M
Net Income	495.17M
EBITDA	793.64M
EBIT	585.28M
Earnings Per Share (EPS)	1.23

Full Income Statement

Balance Sheet

The company has 2.50 billion in cash and 2.39 billion in debt, giving a net cash position of 109.36 million.

Cash & Cash Equivalents	2.50B
Total Debt	2.39B
Net Cash	109.36M
Net Cash Per Share	n/a
Equity (Book Value)	2.10B
Book Value Per Share	5.35
Working Capital	1.40B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 891.99 million and capital expenditures -359.81 million, giving a free cash flow of 532.18 million.

Operating Cash Flow	891.99M
Capital Expenditures	-359.81M
Free Cash Flow	532.18M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.43%, with operating and profit margins of 15.25% and 12.90%.

Gross Margin	59.43%
Operating Margin	15.25%
Pretax Margin	17.62%
Profit Margin	12.90%
EBITDA Margin	20.68%
EBIT Margin	15.25%
FCF Margin	13.87%

Dividends & Yields

DexCom does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.45%
Shareholder Yield	n/a
Earnings Yield	1.71%
FCF Yield	1.84%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.

Last Split Date	Jun 13, 2022
Split Type	Forward
Split Ratio	4

Scores

DexCom has an Altman Z-Score of 6.35 and a Piotroski F-Score of 5.

Altman Z-Score	6.35
Piotroski F-Score	5